- Home
- SGP vs NBTX Comparison
SGP vs NBTX Comparison
Compare SGP & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGP | NBTX |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.9M | 1.0B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SGP | NBTX |
|---|---|---|
| Price | $22.52 | $29.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $45.00 | $26.00 |
| AVG Volume (30 Days) | ★ 100.8K | 52.2K |
| Earning Date | 03-26-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.41 | $2.99 |
| 52 Week High | $30.56 | $41.89 |
Technical Indicators
Market Signals| Indicator | SGP | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.50 | 49.56 |
| Support Level | N/A | $20.11 |
| Resistance Level | $29.83 | $30.23 |
| Average True Range (ATR) | 1.78 | 1.99 |
| MACD | -0.39 | -0.69 |
| Stochastic Oscillator | 10.49 | 13.69 |
Price Performance
Historical ComparisonAbout SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.